# HUTCHMED (China) Ltd: Form 20-F for the period ended Dec 31, 2021

- Company: [HUTCHMED (China) Ltd](/companies/hcm.md) (CIK 1648257)
- Form: 20-F
- Filed: 2022-03-03
- Accepted by EDGAR: Mar 3, 2022, 09:24 ET
- Period: 2021-12-31
- Accession: 0001104659-22-029752
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1648257/000110465922029752/hcm-20211231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1648257/000110465922029752/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $356.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2021-01-01 to 2021-12-31 | $299.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −$328.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2021-01-01 to 2021-12-31 | $592.0k | us-gaap:InterestExpense |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | $11.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | −$194.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2021-01-01 to 2021-12-31 | 792,684,524 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$204.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $16.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2021-01-01 to 2021-12-31 | $27.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-12-31 | $377.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $1.21bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $1.37bn | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $311.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $333.1m | us-gaap:Liabilities |
| Current portion of debt | at 2021-12-31 | $26.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-12-31 | $986.9m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2021-12-31 | 864,530,850 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1648257/000110465922029752/hcm-20211231x20f.htm

Filed Mar 3, 2022.
Source: SEC EDGAR, the filing index for accession 0001104659-22-029752. Last ingested by Listed: Nov 5, 2026, 11:21 ET. No prices; not investment advice.